Moderna (MRNA) Stock Up 23% on Positive Data for Its Coronavirus Vaccine Candidate

UTC by Teuta Franjkovic · 4 min read
Moderna (MRNA) Stock Up 23% on Positive Data for Its Coronavirus Vaccine Candidate
Photo: Depositphotos

Moderna said its experimental coronavirus vaccine demonstrated immune responses in some of the healthy volunteers who were vaccinated in a clinical study. MRNA stock is up.

There seems to be great news coming from American biotechnology company Moderna Inc (NASDAQ: MRNA). An experimental coronavirus vaccine that Moderna is evolving for a longer period now is started to show encouraging early signs that it can make an immune-system response in the body that could help to fight COVID-19 virus, as per the sampling of data from a small, first human trial of the inoculation. The news has a very positive impact on Moderna (MRNA) stock. Now it is 23% up, at $82.50.

Broader markets rose as well, with S&P 500 futures and European stocks trading near session highs. The company said it will report full results from the trial later.

The company stated that the study was mainly recreated to watch for the safety of the vaccine itself and showed no evident warning signs in a small phase 1 trial. The trial is being run with the U.S. government, and Moderna intends to continue developing it to further testing.

A vaccine is currently treated as a crucial move toward lifting social-distancing measures and safely reopening borders, schools and events around the globe. The new coronavirus, known as SARS-CoV-2, has infected more than 4.8 million people and killed over 317,000, propelling a global race by pharmaceutic companies, academic institutions and governments to find a cure.

Two Lower Moderna Coronavirus Vaccine Dose Levels Better Responding

Experts were also monitoring the blood samples from the test subjects and questioned if the vaccine helped them achieve antibodies that could combat an infection. The researchers revealed that at two lower dose levels that were used in the study, levels of antibodies found after getting a second shot of the vaccine either made even or surpassed the levels of antibodies found in patients who had recovered from the virus.

They looked at both the number of coronavirus antibodies produced and in a smaller batch of people if those antibodies were sufficient to stop the virus infecting cells in test-tube experiments. In 25 people who got either of the two smaller doses used in the study, researchers reported that the levels of antibodies equaled or exceeded the levels of antibodies found in patients who had recovered from the virus.

The second test was done by valuing the quality of those antibodies and it was only applicable to eight people because it needs more time in order to be done. However, in all eight people, the vaccine successfully aroused the body to create antibodies able to neutralize the virus in the test tube, so it can no longer infect cells.

Moderna Chief Executive Officer Stephane Bancel said:

“This is a very good sign that we make an antibody that can stop the virus from replicating. The data couldn’t have been better.”

Bancel also noted that safety profile seems to be satisfying, and the results were typical for any vaccine taken, meaning injection site pain and redness, and temporary fever or chills that vanishes on its own.

Bancel added the company had the urge to release the provisional data from the trial because of the high level of public interest in the vaccine itself. A phase 2 trial is expected to begin shortly, and Moderna stated a final-stage trial will begin in July. Bancel said the phase 3 trial will probably add on more thousands of healthy volunteers.

The Newest Vaccine Technology

Most vaccines either have some non-active pieces of a virus or some proteins from a virus made through genetic engineering. When injected into the body, they generate a abiding immune response comparable to that of a person who has been infected and recovered.

On the contrary, the mRNA technology being used by Moderna and several other banks on the body’s own cells to produce viral proteins. Once injected into the body, the RNA goes inside the human cells and encourages them to make virus-like proteins, in this case, the “spike” protein on the surface of the coronavirus. If the vaccine is legit, those proteins then push the body to generate protective antibodies.

The fact is, that this technology is still pretty new and hasn’t been used in an approved vaccine before. Still, it allows scientists to move fast into trials. Moderna started working on its Covid-19 vaccine at the same time as Chinese scientists put out the gene sequence for the virus in January. By late February, Moderna already conveyed the first coronavirus candidate vaccine group to researchers at the U.S. National Institutes of Health. In March, the first healthy volunteer received a dose in the government-sponsored safety trial.

Business News, Market News, News, Stocks
Teuta Franjkovic

Experienced creative professional focusing on financial and political analysis, editing daily newspapers and news sites, economical and political journalism, consulting, PR and Marketing. Teuta’s passion is to create new opportunities and bring people together.

Related Articles